Virios Therapeutics (formerly known as Innovative Med Concepts) is a biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia. Its lead candidate IMC-1 is a fixed-dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress herpes simplex virus-1 (HSV-1) activation and replication, with the end goal of reducing viral-mediated disease burden.
|HQ||Alpharetta, GA, US||Map|
Net income (Q1, 2021)
EBIT (Q1, 2021)
Market capitalization (20-Sept-2021)
Closing stock price (20-Sept-2021)
When was Virios Therapeutics founded?
Virios Therapeutics was founded in 2012.
Who are Virios Therapeutics key executives?
Virios Therapeutics's key executives are Greg Duncan, Ralph Grosswald and R. Michael Gendreau.
How many employees does Virios Therapeutics have?
Virios Therapeutics has 4 employees.
Who are Virios Therapeutics competitors?
Competitors of Virios Therapeutics include VectorY, Theolytics and oncomed.
Where is Virios Therapeutics headquarters?
Virios Therapeutics headquarters is located at 44 Milton Ave, Alpharetta.
Where are Virios Therapeutics offices?
Virios Therapeutics has an office in Alpharetta.
How many offices does Virios Therapeutics have?
Virios Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies